Excellent
Fully Aligned
Patient Risk:
Low
Summary
The AI claim is fully supported by the supplied QAMZOVA label text, including boxed/major warning elements: serious CV thrombotic events (MI/stroke), serious GI events (bleeding/ulceration/perforation) that can be fatal, earlier onset and higher-dose risk, lowest effective dose/shortest duration mitigation, and CABG contraindication.
Category Scores
Accurate Statements
QAMZOVA (meloxicam) can cause serious cardiovascular thrombotic events (including MI and stroke) and serious gastrointestinal adverse events (including bleeding, ulceration, and perforation), which can be fatal.
Supported by label Sections 5.1 and 5.2: CV thrombotic events including MI and stroke; serious GI adverse events including bleeding, ulceration, and perforation that can be fatal.
Risk may begin early and is higher at higher doses.
Supported by label Section 5.1: risk may begin as early as the first weeks; increase observed most consistently at higher doses.
Use lowest effective dose for shortest duration.
Supported by label Section 5.1 (risk minimization: lowest effective dose for shortest duration possible) and also consistent with GI risk minimization strategies in Section 5.2.
Avoid in CABG setting.
Supported by label Section 4 contraindication in CABG setting and related warning context in Section 5.1.
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
No unsafe or contradictory claims were made; all described risks and mitigations are supported by the supplied label warning/contraindication text.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement